The primary objective of the study is to evaluate real-world effectiveness of treatment with Repatha® in combination with SOC, compared with SOC alone, on the risk for cardiovascular (CV) death, myocardial infarction (MI), stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in participants with established atherosclerotic CV disease (ASCVD) treated with SOC, according to local clinical practice.
Adult participants ≥ 18 years of age.
Participants or participant's legally authorized representative has provided informed consent to participate in this study.
Prescribed Repatha® in addition to an existing SOC treatment according to local guidelines and approved label.
Already received SOC treatment prior to enrollment.
Stroke within past 1 month.
Known hemorrhagic stroke at any time.
Stroke due to thromboembolic event.
Any prior use of Repatha® or other proprotein convertase subtilisin/kexin type 9 inhibition treatments within past 6 months prior to enrollment.
The study population comprises Chinese participants with established ASCVD treated with Repatha® in combination with SOC or with SOC alone in a clinical setting which includes any primary through tertiary healthcare setting where Repatha® is prescribed.
Cohort
Prospective
Not listed
Time to CV Death, MI, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization, Whichever Occurs First
Time to CV Death, MI, or Stroke, Whichever Occurs First
Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline
Percent Change in LDL-C From Baseline
Number of Participants Who Experienced Adverse Events
